Mga Batayang Estadistika
| LEI | 5299001N23WBO4XQ2P60 |
| CIK | 316253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enzo Biochem, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 333-271911 No. 333-272727 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-271911 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-272727 UNDER THE SECURITIES ACT OF 1933 ENZO BIOCHEM, INC. (Exact name |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
FORM OF CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF ENZO BIOCHEM, INC. ARTICLE I Exhibit 3.1 FORM OF CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF ENZO BIOCHEM, INC. ARTICLE I The name of the corporation is “Enzo Biochem, Inc.” (the “Corporation”). ARTICLE II The purpose for which the Corporation is formed is to engage in any lawful act or activity for which corporations may be organized under the New York Business Corporation Law, provided that the Corporati |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. ARTICLE I OFFICES Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. ARTICLE I OFFICES Section 1.01 Principal Office. The principal office of the corporation shall be located at such place within or without the State of New York as the board of directors may from time to time determine. Section 1.02 Other Offices. The corporation may also have offices and places of business at such other places within a |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 333-271911 No. 333-272727 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-271911 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT No. 333-272727 UNDER THE SECURITIES ACT OF 1933 ENZO BIOCHEM, INC. (Exact name |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
As filed with the Securities and Exchange Commission on August 20, 2025 As filed with the Securities and Exchange Commission on August 20, 2025 No. 33-88826 No. 333-87153 No. 333-89308 No. 333-123712 No. 333-172127 No. 333-197028 No. 333-226799 No. 333-236958 No. 333-252159 No. 333-260894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-8 REGISTRATION STATEMENT No. 33-88826 Post-Effective Amendment No. 1 |
|
| August 20, 2025 |
OMB APPROVAL UNITED STATES OMB Number: 3235-0167 SECURITIES AND EXCHANGE COMMISSION Expires: August 31, 2027 Washington, D. |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 19, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Enzo Biochem, Inc. |
|
| July 7, 2025 |
PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION, DATED JULY 3, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 24, 2025 |
warrant Cancellation Agreement Exhibit 10.1 warrant Cancellation Agreement This WARRANT Cancellation Agreement (this “Agreement”) is made and entered into as of this , 2025, by and between (the “Warrantholder”), Enzo Biochem, Inc., a New York corporation (the “Company”) in contemplation of a Fundamental Transaction. Capitalized terms used herein and not otherwise defined shall have the meanings given to such terms in the Common |
|
| June 24, 2025 |
Exhibit 2.1 Agreement and Plan of merger by and among Bethpage Parent, Inc., Bethpage Merger Sub, Inc. and Enzo Biochem, Inc. Dated as of June 23, 2025 Table of Contents Page ARTICLE 1 THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Effective Time of Merger 2 Section 1.3 General Effects of Merger 2 Section 1.4 Effect of Merger on Capital Stock 2 Section 1.5 Treatment of Company Options, Company |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Consent Statement ☐ Confidential, for Use of the Commission Only |
|
| June 24, 2025 |
Exhibit 99.1 Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that on June 23, 2025, following the market close, it e |
|
| June 24, 2025 |
Exhibit 99.1 Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (OTCQX: ENZB) (“Enzo” or the “Company”) today announced that on June 23, 2025, following the market close, it e |
|
| June 24, 2025 |
Exhibit 2.1 Agreement and Plan of merger by and among Bethpage Parent, Inc., Bethpage Merger Sub, Inc. and Enzo Biochem, Inc. Dated as of June 23, 2025 Table of Contents Page ARTICLE 1 THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Effective Time of Merger 2 Section 1.3 General Effects of Merger 2 Section 1.4 Effect of Merger on Capital Stock 2 Section 1.5 Treatment of Company Options, Company |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 24, 2025 |
Exhibit 10.2 VOTING AND Support AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of [●], 2025, by and among [●] Parent, Inc., a Delaware corporation (“Parent”), [●] Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the stockholders of Enzo Biochem, Inc., a New York corporation (the “Company”) listed on Sch |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 24, 2025 |
warrant Cancellation Agreement Exhibit 10.1 warrant Cancellation Agreement This WARRANT Cancellation Agreement (this “Agreement”) is made and entered into as of this , 2025, by and between (the “Warrantholder”), Enzo Biochem, Inc., a New York corporation (the “Company”) in contemplation of a Fundamental Transaction. Capitalized terms used herein and not otherwise defined shall have the meanings given to such terms in the Common |
|
| June 24, 2025 |
Exhibit 10.2 VOTING AND Support AGREEMENT This VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of [●], 2025, by and among [●] Parent, Inc., a Delaware corporation (“Parent”), [●] Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the stockholders of Enzo Biochem, Inc., a New York corporation (the “Company”) listed on Sch |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM |
|
| April 22, 2025 |
Exhibit 99.1 Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction Forms Special Committee of the Board to Lead Evaluation of Viable Options for Maximizing Shareholder Value Engages Independent Financial and Legal Advisors to Support Thorough Process Remains Committed to Maintaining Focus on Cost Containment, Cash Preserv |
|
| April 22, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(B) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-09974 ENZO BIOCHEM, INC. THE NEW YORK STOCK EXCHANGE (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 21 Execu |
|
| March 31, 2025 |
Exhibit 99.1 Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| March 18, 2025 |
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results Exhibit 99.1 Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results FARMINGDALE, N.Y., March 17, 2025 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal second quarter ended January 31, 2025, with sequential quarter improvement in revenue, gross margin and operating profit / loss. Financial Highlights ● The Company’s s |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| January 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 15, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 13, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fil |
|
| January 14, 2025 |
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules Exhibit 99.1 Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules FARMINGDALE, N.Y., January 14, 2025 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01B and Section 802.01C of the NYSE Listed Company Manual |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2025 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 30, 2024 |
ENZO BIOCHEM, INC. (in thousands, except per share data) Exhibit 99.1 Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had a |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 29, 2024 |
Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31 (b) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| October 29, 2024 |
Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 31 (a) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| October 29, 2024 |
Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 32 (b) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patricia Eckert, Chief Financia |
|
| October 29, 2024 |
Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 32 (a) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kara Cannon, Chief Executive Of |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM, INC. |
|
| October 29, 2024 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK General Matters Pursuant to our Certificate of Incorporation, as amended, the total amount of our authorized capital stock is 100,000,000 shares, which consists of 75,000,000 shares of authorized common stock, par value $0.01 per share, and 25,000,000 shares of authorized preferred stock, par value $0.01 per share. As of October 25, 2024, we had outstanding |
|
| October 29, 2024 |
List of subsidiaries of the Company Exhibit 21 List of subsidiaries of the Company Enzo Clinical Labs, Inc., a New York Corporation Enzo Life Sciences, Inc., a New York Corporation Enzo Life Sciences (ELS) AG, in Lausen, Switzerland, a wholly-owned subsidiary of Enzo Life Sciences, Inc. Enzo Therapeutics, Inc., a New York Corporation Enzo Realty LLC, a New York Corporation Enzo Realty II, LLC, a New York Corporation |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission F |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 25, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), dated as of June 03, 2024 (the “Effective Date”), is made between Enzo Biochem, Inc., a New York corporation, with its principal office at 21 Executive Boulevard, Farmingdale, New York 11735 (the “Company”) and Patricia Eckert (the “Executive”) (each individually a “Party”, and collectively the “Part |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM |
|
| May 24, 2024 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (the “Agreement”), dated as of January 1, 2024 (the “Effective Date”), is made between Enzo Biochem, Inc., a New York corporation, with its principal office at 81 Executive Boulevard, Farmingdale, New York 11735 (the “Company”) and Kara Cannon (the “Executive”) (e |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission File |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| March 13, 2024 |
ENZO BIOCHEM, INC. (in thousands, except per share data) Exhibit 99.1 Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights ● The Company's Life Science division's second-quarter revenue of $8.5 million improv |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 14, 2024 |
ENZ / Enzo Biochem, Inc. / 1 MAIN CAPITAL MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm245967d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enzo Biochem, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 294100102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement) Check t |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2024 ENZO BIOCHEM, INC. (Exact name of registrant as specified in its charter) New York 001-09974 13-2866202 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 1, 2024 |
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments Exhibit 99.1 Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments FARMINGDALE, NY, Feb 1, 2024 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual Shareholder Me |
|
| December 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-0997 |
|
| November 3, 2023 |
Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (a) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| November 3, 2023 |
Separation Agreement and General Release between Hamid Erfanian and Enzo Biochem, Inc. EXHIBIT 10 (x) EXECUTION COPY SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) by and between Hamid Erfanian (“Executive” or “you”) and Enzo Biochem, Inc. |
|
| November 3, 2023 |
EXHIBIT 10 (w) AMENDMENT AGREEMENT This Amendment Agreement (“Agreement”), dated as of October 4, 2023, is made by and between JGB Capital, LP, JGB Partners, LP and JGB (Cayman) Sussex Ltd. |
|
| November 3, 2023 |
Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (b) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Patricia Eckert, Interim Chief |
|
| November 3, 2023 |
Exhibit 10 (y) SETTLEMENT AGREEMENT This Settlement Agreement, dated as of October 24, 2023 ("Agreement"), is entered into by and between Barry Weiner ("Weiner"), Shahla Weiner, Roya Weiner, and Jonathan Weiner (collectively, the foregoing are the "Weiner Parties" and each is a "Weiner Party"), Enzo Biochem, Inc. |
|
| November 3, 2023 |
Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (b) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| November 3, 2023 |
Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (a) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kara Cannon, Interim Chief Exec |
|
| November 3, 2023 |
EXHIBIT 97.1 ENZO BIOCHEM, INC. (the “Company”) Compensation Clawback Policy Effective Date: October 1, 2023 1. Purpose. The Company has adopted this Policy to comply with Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, and Section 303A.14 of the NYSE Listed Company Manual, which require the recovery of certain f |
|
| November 3, 2023 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK General Matters Pursuant to our Certificate of Incorporation, as amended, the total amount of our authorized capital stock is 100,000,000 shares, which consists of 75,000,000 shares of authorized common stock, par value $0.01 per share, and 25,000,000 shares of authorized preferred stock, par value $0.01 per share. As of October 27, 2023, we had outstanding |
|
| November 3, 2023 |
List of subsidiaries of the Company EXHIBIT 21 List of subsidiaries of the Company Enzo Clinical Labs, Inc., a New York Corporation Enzo Life Sciences, Inc., a New York Corporation Enzo Life Sciences (ELS) AG, in Lausen, Switzerland, a wholly-owned subsidiary of Enzo Life Sciences, Inc. Enzo Therapeutics, Inc., a New York Corporation Enzo Realty LLC, a New York Corporation Enzo Realty II, LLC, a New York Corporation |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM, INC. |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 001-09974 CUSIP NUMBER 294100102 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: July 31, 2023 ☐ Transition Report |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 Enzo Biochem, Inc. |
|
| October 30, 2023 |
Amended and Restated Bylaws (15) Exhibit 3.1 AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. (a New York Corporation) (as amended and restated as of October 26, 2023) ARTICLE I MEETING OF SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of the shareholders of Enzo Biochem, Inc., (hereinafter called the “Corporation”) for the election of directors and for the transaction of such other business as may come before the m |
|
| September 11, 2023 |
ENZ / Enzo Biochem, Inc. / 1 MAIN CAPITAL MANAGEMENT, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enzo Biochem, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 294100102 (CUSIP Number) September 1, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rule p |
|
| September 11, 2023 |
EX-99.1 2 tm2325875d1ex-1.htm EXHIBIT 1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.01 par value per share, of Enzo Biochem, Inc., and further agree |
|
| September 7, 2023 |
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO Exhibit 99.1 Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Offi |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 5, 2023 Enzo Biochem, Inc. |
|
| July 28, 2023 |
Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION (in thousands, except share and per share data) The following unaudited pro forma condensed consolidated financial information is based upon the historical consolidated statements of Enzo Biochem, Inc., a New York corporation (the “Company”), adjusted to give effect to the sale (the “Asset Sale”) of substantially all the |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| July 24, 2023 |
Exhibit 99.1 Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp Significant value unlocked for Enzo shareholders with continued focus on life sciences. FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2023 Enzo Biochem, Inc. |
|
| July 24, 2023 |
ENZ / Enzo Biochem, Inc. / Laboratory Corp Of America Holdings - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Enzo Biochem, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 294100102 (CUSIP Number) Sandra van der Vaart Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Laboratory |
|
| July 19, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-272727 PROSPECTUS ENZO BIOCHEM, INC. 1,000,000 Shares of Common Stock Issuable Upon Exercise of Warrants 2,527,808 Shares of Common Stock Issuable Upon Conversion of Debentures This prospectus relates to the resale, from time to time, of up to 3,527,808 shares (the “Shares”) of our common stock, $0.01 par value per share (“Common Stock”), by th |
|
| July 18, 2023 |
July 18, 2023 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Katherine Bagley Re: ENZO BIOCHEM INC Amendment No. 1 to Registration Statement on Form S-3 Filed July 10, 2023 File No. 333-272727 Dear Ms. Ansart and Ms. Bagley: I am writing to |
|
| July 18, 2023 |
Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 July 18, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Enzo Biochem, Inc. (CIK 000316253) Registration Statement No. 333-272727 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Enzo Biochem, Inc. (the “Registrant”) hereby requests acc |
|
| July 18, 2023 |
As filed with the Securities and Exchange Commission on July 18, 2023 As filed with the Securities and Exchange Commission on July 18, 2023 Registration No. |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2023 Enzo Biochem, Inc. |
|
| July 10, 2023 |
As filed with the Securities and Exchange Commission on July 10, 2023 As filed with the Securities and Exchange Commission on July 10, 2023 Registration No. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 3, 2023 Enzo Biochem, Inc. |
|
| July 10, 2023 |
July 10, 2023 VIA EDGAR AND EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Katherine Bagley Re: ENZO BIOCHEM INC Registration Statement on Form S-3 Filed June 16, 2023 File No. 333-272727 Dear Ms. Ansart and Ms. Bagley: I am writing to submit the respons |
|
| July 10, 2023 |
Exhibit 2.1 CONFIDENTIAL Execution Version AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This Amendment No. 1 to the Asset Purchase Agreement (this “Amendment”) is entered into as of July 3, 2023 (the “Amendment Effective Date”), by and among Laboratory Corporation of America Holdings, a Delaware corporation (“Buyer”), Enzo Clinical Labs, Inc., a New York corporation (“Seller”), and Enzo Biochem, In |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 22, 2023 |
ENZO BIOCHEM, INC. Up to $30,000,000 Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-271911 PROSPECTUS ENZO BIOCHEM, INC. Up to $30,000,000 Common Stock We have entered into a sales agreement with B. Riley Securities, Inc. relating to shares of our common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of u |
|
| June 20, 2023 |
Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 June 20, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Enzo Biochem, Inc. (CIK 000316253) Registration Statement No. 333-271911 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Enzo Biochem, Inc. (the “Registrant”) hereby requests acc |
|
| June 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Enzo Biochem, Inc. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 Enzo Biochem, Inc. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 16, 2023 |
As filed with the Securities and Exchange Commission on June 16, 2023 As filed with the Securities and Exchange Commission on June 16, 2023 Registration No. |
|
| June 16, 2023 |
Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION (in thousands, except share and per share data) The following unaudited pro forma condensed consolidated financial information is based upon the historical consolidated statements of Enzo Biochem, Inc., a New York corporation (the “Company”), adjusted to give effect to the sale (the “Asset Sale”) of substantially all the |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM |
|
| June 9, 2023 |
Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 Enzo Biochem, Inc. 81 Executive Blvd., Suite 3 Farmingdale, NY, 11735 June 9, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Enzo Biochem, Inc. (CIK 000316253) Registration Statement No. 333-271911 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: Enzo Biochem, Inc. (the “Registrant”) hereby requests acce |
|
| June 9, 2023 |
NT 10-Q 1 ea180105-nt10qenzo.htm NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2023 Enzo Biochem, Inc. |
|
| May 26, 2023 |
As filed with the Securities and Exchange Commission on May 25, 2023 S-3/A 1 ea179145-s3a1enzobiochem.htm AMENDMENT NO. 1 TO FORM S-3 As filed with the Securities and Exchange Commission on May 25, 2023 Registration No. 333-271911 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enzo Biochem, Inc. (Exact name of registrant as specified in its charter) New York |
|
| May 22, 2023 |
Exhibit 10.4 Exhibit F SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of May 19, 2023 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of the purchasers signatory (together with their permitted assigns, the “Purchasers”) to that certain Securities Purchase Agreement, dated |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 22, 2023 Enzo Biochem, Inc. |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2023 Enzo Biochem, Inc. |
|
| May 22, 2023 |
Exhibit 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of May 19 2023 (this “Agreement”), is among Enzo Biochem, Inc., a New York corporation (the “Company”), the Subsidiaries of the Company party hereto (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”), JGB Collateral, LLC, a Delaware limited liability company, as the collateral agent (the “Agent”), and |
|
| May 22, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 22, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 19, 2023, between Enzo Biochem, Inc., a New York corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agree |
|
| May 22, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 19, 2023, between Enzo Biochem, Inc., a New York corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”), and JGB Collateral LLC, a Delaware limited liability c |
|
| May 22, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| May 15, 2023 |
Sales Agreement, dated May 12, 2023, between Enzo Biochem, Inc. and B. Riley Securities, Inc. Exhibit 1.2 ENZO BIOCHEM, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement May 12, 2023 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Enzo Biochem, Inc., a New York corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. (the “Agent”) as follows: 1. Issuance and Sale of Sh |
|
| May 15, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Enzo Biochem, Inc. |
|
| May 15, 2023 |
Power of Attorney (contained on page II-5) As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Enzo Biochem, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 294100102 (CUSIP Number) BRADLEY L. RADOFF 2 |
|
| May 10, 2023 |
Exhibit 99.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (this “Agreement”), dated as of [•], 2023, is by and between Laboratory Corporation of America Holdings, a Delaware corporation (“Buyer”) and [Stockholder Name] (the “Stockholder”). WHEREAS, as of the date hereof, the Stockholder is the record and beneficial owner (as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the “Exchang |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2023 Enzo Biochem, Inc. |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2023 Enzo Biochem, Inc. |
|
| April 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Schedule 14A (Form Type) Enzo Biochem, Inc. |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2023 Enzo Biochem, Inc. |
|
| April 5, 2023 |
Exhibit 10.1 CREDIT AGREEMENT by and among ENZO CLINICAL LABS, INC., ENZO LIFE SCIENCES, INC., such other Persons joined hereto as a Borrower from time to time, as Borrowers, and GEMINO HEALTHCARE FINANCE, LLC d/b/a SLR HEALTHCARE ABL, as Lender Dated as of March 31, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS, ACCOUNTING TERMS AND PRINCIPLES OF CONSTRUCTION 1 1.01 Terms Defined 1 1.02 Accounting |
|
| March 27, 2023 |
ENZ / Enzo Biochem, Inc. / Laboratory Corp Of America Holdings - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Enzo Biochem, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 294100102 (CUSIP Number) Sandra van der Vaart Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Laboratory Co |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| March 16, 2023 |
DEFA14A 1 ea175132-8kenzobiochem.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Enzo Biochem, Inc. (Exact Name of Registrant as Specified in Its Charter) New York (State or Other Jurisdiction of Inc |
|
| March 16, 2023 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT dated as of March 16, 2023 by and among LABORATORY CORPORATION OF AMERICA HOLDINGS, Enzo Clinical Labs, Inc. and ENZO BIOCHEM, INC. TABLE OF CONTENTS Page Article I DEFINITIONS 2 1.1 Definitions 2 1.2 Other Definitional Provisions 23 Article II SALE AND PURCHASE OF ACQUIRED ASSETS 24 2.1 Transfer of Acquired Assets 24 2.2 The Closing 24 2.3 Purchase Price 24 2. |
|
| March 16, 2023 |
Press Release, dated March 16, 2023, issued by Enzo Biochem, Inc. Exhibit 99.1 Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp Significant value unlocked for Enzo shareholders with continued focus on remaining businesses. FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical |
|
| March 16, 2023 |
Exhibit 99.1 Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp Significant value unlocked for Enzo shareholders with continued focus on remaining businesses. FARMINGDALE, NY, March 16, 2023 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical |
|
| March 16, 2023 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT dated as of March 16, 2023 by and among LABORATORY CORPORATION OF AMERICA HOLDINGS, Enzo Clinical Labs, Inc. and ENZO BIOCHEM, INC. TABLE OF CONTENTS Page Article I DEFINITIONS 2 1.1 Definitions 2 1.2 Other Definitional Provisions 23 Article II SALE AND PURCHASE OF ACQUIRED ASSETS 24 2.1 Transfer of Acquired Assets 24 2.2 The Closing 24 2.3 Purchase Price 24 2. |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 16, 2023 Enzo Biochem, Inc. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER CUSIP NUMBER (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: January 31, 2023 ☐ Transition Report on Form 10-K ☐ Tr |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2023 Enzo Biochem, Inc. |
|
| January 23, 2023 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2022 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-0997 |
|
| November 23, 2022 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240. |
|
| November 4, 2022 |
Amended and Restated Employment Agreement with Hamid Erfanian (b) Exhibit 10.2 SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Second Amended and Restated Executive Employment Agreement (the “Agreement”), dated as of October 14, 2021 (the “Effective Date”), as amended March 24, 2022 and further amended October 20, 2022 (the “Amendment Date”), made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 (October 20, 2022) Enzo Biochem, Inc. |
|
| November 4, 2022 |
Amended and Restated Employment Agreement with Kara Cannon (a) Exhibit 10.1 FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), dated as of March 21, 2022 (the “Effective Date”), as amended October 20, 2022 (the Amendment Date”), made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022 (the “Company”) and Kara Cannon (the “Exe |
|
| October 26, 2022 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. |
|
| October 20, 2022 |
Exhibit 99.1 Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO - David Bench resigning to pursue a new career opportunity - NEW YORK, NY, October 20, 2022 ? Enzo Biochem, Inc. (NYSE: ENZ) (?Enzo? or the ?Company?), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO). Ms. Eckert?s appointment |
|
| October 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 20, 2022 (October 15, 2022) ENZO BIOCHEM, INC. (Exact Name of Registrant as Specified in its Charter) New York 001-09974 13-2866202 (State or Other Jurisdiction of Incorporati |
|
| October 14, 2022 |
Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (a) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Hamid Erfanian, Chief Executive |
|
| October 14, 2022 |
Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (b) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| October 14, 2022 |
Sublease agreement between Enzo Biochem, Inc. and Siemens Corporation Exhibit 10(ae) |
|
| October 14, 2022 |
List of subsidiaries of the Company EXHIBIT 21 List of subsidiaries of the Company Enzo Clinical Labs, Inc., a New York Corporation Enzo Life Sciences, Inc., a New York Corporation Enzo Life Sciences (ELS) AG, in Lausen, Switzerland, a wholly-owned subsidiary of Enzo Life Sciences, Inc. Enzo Therapeutics, Inc., a New York Corporation Enzo Realty LLC, a New York Corporation Enzo Realty II, LLC, a New York Corporation |
|
| October 14, 2022 |
Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (b) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Bench, Chief Financial Of |
|
| October 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM, INC. |
|
| October 14, 2022 |
Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (a) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| June 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Amendment No. |
|
| May 6, 2022 |
Amended and Restated Certificate of Incorporation of Enzo Biochem, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ENZO BIOCHEM, INC. Under Section 807 of the Business Corporation Law The undersigned, for the purpose of restating the corporation?s Certificate of Incorporation, pursuant to Section 807 of the Business Corporation Law of the State of New York, does hereby certify: FIRST: The name under which the corporation was formed is Enzo Biochem, Inc. SECO |
|
| May 6, 2022 |
Amended and Restated By-Laws of Enzo Biochem, Inc. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. (a New York Corporation) (as amended and restated as of April 25, 2022) ARTICLE I MEETING OF SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of the shareholders of Enzo Biochem, Inc., (hereinafter called the ?Corporation?) for the election of directors and for the transaction of such other business as may come before the mee |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 Enzo Biochem, Inc. |
|
| April 27, 2022 |
Amended and restated Bylaws (34) Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. (a New York Corporation) (as amended and restated as of April 25, 2022) ARTICLE I MEETING OF SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of the shareholders of Enzo Biochem, Inc., (hereinafter called the ?Corporation?) for the election of directors and for the transaction of such other business as may come before the mee |
|
| April 27, 2022 |
Restated Certificate of Incorporation (1) Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ENZO BIOCHEM, INC. Under Section 807 of the Business Corporation Law The undersigned, for the purpose of restating the corporation?s Certificate of Incorporation, pursuant to Section 807 of the Business Corporation Law of the State of New York, does hereby certify: FIRST: The name under which the corporation was formed is Enzo Biochem, Inc. SECO |
|
| April 8, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 8, 2022 Enzo Biochem, Inc. |
|
| April 6, 2022 |
DEFA14A 1 ea158137-defa14aenzobio.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Under Rule 14a-12 Enzo Biochem, Inc. |
|
| April 1, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 31, 2022 Enzo Biochem, Inc. |
|
| March 30, 2022 |
Exhibit 10.3 FIRST AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This First Amended and Restated Executive Employment Agreement (the ?Agreement?), dated as of October 14, 2021, as amended March 24, 2022, made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022, (the ?Company?) and Hamid Erfanian (the ?Executive?) (coll |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2022 Enzo Biochem, Inc. |
|
| March 30, 2022 |
Exhibit 99.1 Enzo Biochem, Inc. 527 Madison Avenue New York, NY 10022 FOR IMMEDIATE RELEASE Enzo Biochem Announces Appointments of David Bench and Kara Cannon to New Executive Management Positions NEW YORK, NY, March 28, 2022 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (?Enzo? or the ?Company?), a leading biosciences and diagnostics company, today announced that Kara Cannon, formerly Chief C |
|
| March 30, 2022 |
Employment Agreement between Enzo Biochem, Inc. and David Bench, effective as of March 24, 2022 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), dated as of March 24, 2022, made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022, (the ?Company?) and David Bench (the ?Executive?) (collectively, the ?Parties?). Whereas, Executive is currently a full-time employee of the |
|
| March 30, 2022 |
Employment Agreement between Enzo Biochem, Inc. and Kara Cannon, effective as of March 24, 2022 Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), dated as of March 24, 2022, made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022 (the ?Company?) and Kara Cannon (the ?Executive?) (collectively, the ?Parties?). Whereas, Executive is currently a full-time employee of the C |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 16) Enzo Biochem, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294100102 (CUSIP Number) James C. Roumell Asset Management, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 (301) 656-8500 (Name, Address and Telephone Number of Pers |
|
| March 25, 2022 |
Exhibit 99.1 March 24, 2022 Via E-mail Craig L. Lukin c/o: Roumell Asset Management, LLC 2 Wisconsin Cir #700 Chevy Chase, Maryland 20815 Email: [email protected] Re: Termination of Joint Filing and Solicitation Agreement, dated September 29, 2021 Dear Craig: The undersigned constitute all the parties to that certain Joint Filing and Solicitation Agreement, dated September 29, 2021 (the ?Agr |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2022 Enzo Biochem, Inc. |
|
| March 18, 2022 |
Exhibit 3.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED BY-LAWS OF ENZO BIOCHEM, INC. (a New York corporation) Article I, Section 8 of the Amended and Restated By-Laws of Enzo Biochem, Inc. is hereby amended and replaced with the following: Section 8. Order of Business. The order of business at all meetings of the shareholders shall be as determined by the chairman of the meeting. The Board may adjour |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| March 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): Februrary 25, 2022 Enzo Biochem, Inc. |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Amendment No. |
|
| February 10, 2022 |
ENZ / Enzo Biochem, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Enzo Biochem Inc. Title of Class of Securities: Common Stock CUSIP Number: 294100102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??R |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2022 Enzo Biochem, Inc. |
|
| January 18, 2022 |
ENZ / Enzo Biochem, Inc. / Evermore Global Advisors, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Enzo Biochem, Inc. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 294100102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Under Rule 14a-12 Enzo Biochem, Inc. |
|
| January 4, 2022 |
Exhibit 99.1 Execution Version COOPERATION AGREEMENT This Cooperation Agreement (this ?Agreement?) is made and entered into as of January 3, 2022 by and among Enzo Biochem, Inc. (the ?Company?) and the entities and natural persons set forth in the signature pages hereto (collectively, the ?Radoff Parties?) (each of the Company and the Radoff Parties, a ?Party? to this Agreement, and collectively, |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2022 Enzo Biochem, Inc. |
|
| January 4, 2022 |
Cooperation agreement by and among Enzo Biochem, Inc. and the Radoff Parties (10) Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this ?Agreement?) is made and entered into as of January 3, 2022 by and among Enzo Biochem, Inc. (the ?Company?) and the entities and natural persons set forth in the signature pages hereto (collectively, the ?Radoff Parties?) (each of the Company and the Radoff Parties, a ?Party? to this Agreement, and collectively, the ?Parties?). RE |
|
| January 4, 2022 |
Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Enzo Biochem, Inc., a New York corporation. This Joint |
|
| January 4, 2022 |
ENZ / Enzo Biochem, Inc. / Radoff Bradley Louis Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 3)1 Enzo Biochem, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 294100102 (CUSIP Number) BRADLEY L. RADOFF 2 |
|
| January 4, 2022 |
Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors Exhibit 99.1 Enzo Biochem, Inc. 527 Madison Avenue New York, NY 10022 FOR IMMEDIATE RELEASE Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem?s Board of Directors NEW YORK, NY, January 3, 2022 (GLOBE NEWSWIRE) - Enzo Biochem, Inc. (NYSE: ENZ) (?Enzo? or the ?Company?), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to |
|
| December 27, 2021 |
ENZ / Enzo Biochem, Inc. / Radoff Bradley Louis Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Enzo Biochem, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 294100102 (CUSIP Number) BRADLEY L. RADOFF 2 |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCH |
|
| December 15, 2021 |
Executive Employment Agreement between the Company and Hamid Erfanian, dated October 14, 2021. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), dated as of October 14, 2021, made between Enzo Biochem, Inc., a New York corporation, with its principal office at 527 Madison Avenue, New York, New York 10022, (the ?Company?) and Hamid Erfanian (the ?Executive?) (collectively, the ?Parties?). Whereas, the Company desires for Executive to provide s |
|
| December 2, 2021 |
O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212. |
|
| December 2, 2021 |
PRRN14A 1 prrn14a10907604712022021.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-0997 |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended July 31, 2021 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-0997 |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| November 15, 2021 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240. |
|
| November 9, 2021 |
Inducement Restricted Stock Unit Grant Notice and Agreement Exhibit 99.1 INDUCEMENT RESTRICTED STOCK UNIT GRANT NOTICE AND AGREEMENT To: Hamid Erfanian (referred to herein as ?Grantee? or ?you?) WHEREAS, Enzo Biochem, Inc. (the ?Company?) desires to employ the Grantee as its Chief Executive Officer; WHEREAS, in an Executive Employment Agreement dated October 14, 2021 (the ?Employment Agreement?), the Company has agreed to grant the Grantee an inducement re |
|
| November 9, 2021 |
As filed with the Securities and Exchange Commission on November 9, 2021 As filed with the Securities and Exchange Commission on November 9, 2021 Registration No. |
|
| November 9, 2021 |
Inducement Option Grant Notice and Agreement Exhibit 99.2 INDUCEMENT STOCK OPTION GRANT NOTICE AND AGREEMENT To: Hamid Erfanian (referred to herein as ?Grantee? or ?you?) WHEREAS, Enzo Biochem, Inc. (the ?Company?) desires to employ the Grantee as its Chief Executive Officer; WHEREAS, in an Executive Employment Agreement dated October 14, 2021 (the ?Employment Agreement?), the Company has agreed to grant the Grantee an inducement stock optio |
|
| October 28, 2021 |
ENZ / Enzo Biochem, Inc. / Harbert Discovery Fund, LP - ENZO BIOCHEM, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 14)* Enzo Biochem, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 294100102 (CUSIP Number) Kevin A. McGovern, Esq. c/o Harbert Discovery Fund, LP 2100 Third Avenue North, Suite 600 Birmingham, AL 35203 (205) 987-5577 with a copy to: E |
|
| October 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| October 22, 2021 |
ENZ / Enzo Biochem, Inc. / Radoff Bradley Louis Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Enzo Biochem, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 294100102 (CUSIP Number) BRADLEY L. RADOFF 2 |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2021 Enzo Biochem, Inc. |
|
| October 18, 2021 |
Exhibit 99.1 Enzo Biochem, Inc. 527 Madison Avenue New York, NY 10022 FOR IMMEDIATE RELEASE HAMID ERFANAIN NAMED CHIEF EXECUTIVE OFFICER OF ENZO BIOCHEM TO ACCELERATE EXPANSION AND COMMERCIALIZATION OF KEY DIAGNOSTIC PLATFORMS Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer NEW YORK, NY, October 18, 2021 (GLOBE NEWSWIRE) - Enzo Biochem, In |
|
| October 12, 2021 |
Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (b) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark one) ? ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM, INC. |
|
| October 12, 2021 |
List of subsidiaries of the Company Exhibit 21 List of subsidiaries of the Company Enzo Clinical Labs, Inc., a New York Corporation Enzo Life Sciences, Inc., a New York Corporation Enzo Life Sciences (ELS) AG, in Lausen, Switzerland, a wholly-owned subsidiary of Enzo Life Sciences, Inc. Enzo Therapeutics, Inc., a New York Corporation Enzo Realty LLC, a New York Corporation Enzo Realty II, LLC, a New York Corporation |
|
| October 12, 2021 |
Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (b) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Bench, Chief Financial Of |
|
| October 12, 2021 |
Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31 (a) CERTIFICATIONS In connection with the Annual Report on Form 10-K of Enzo Biochem, Inc. |
|
| October 12, 2021 |
Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 EXHIBIT 32 (a) CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzo Biochem, Inc., and Subsidiaries (“the Company”) on Form 10-K for the fiscal year ended July 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Elazar Rabbani, Ph.D., Chief Ex |
|
| October 6, 2021 |
Group Agreement, dated September 29, 2021. GROUP AGREEMENT WHEREAS, certain of the undersigned are shareholders, direct or beneficial, of Enzo Biochem, Inc. |
|
| October 6, 2021 |
ENZ / Enzo Biochem, Inc. / Radoff Bradley Louis - THE SCHEDULE 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. |
|
| October 6, 2021 |
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Bradley L. |
|
| October 1, 2021 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ?240. |
|
| September 30, 2021 |
JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.2 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Enzo BioChem, Inc., a New York corporation (the ?Company?); WHEREAS, Roumell Opportunistic Value Fund (the ?Fund?), Roumell Asset Management, LLC, a Maryland limited liability company (?Roumell?), James C. Roumell, Susanne L. Meline and Edward Terino wish to form a gr |
|
| September 30, 2021 |
ROUMELL ASSET MANAGEMENT, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 Exhibit 99.3 ROUMELL ASSET MANAGEMENT, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 September [?], 2021 [] Re: Enzo Biochem, Inc. Dear []: Thank you for agreeing to serve as a nominee for election to the Board of Directors of Enzo Biochem, Inc. (the ?Company?) in connection with the proxy solicitation that Roumell Opportunistic Value Fund (the ?Fund?) is considering undertaking to nomin |
|
| September 30, 2021 |
Termination of Joint Filing and Solicitation Agreement, dated September 29, 2021 Exhibit 99.1 September 29, 2021 Via E-mail Craig L. Lukin c/o: Roumell Asset Management, LLC 2 Wisconsin Cir #700 Chevy Chase, Maryland 20815 Email: [email protected] Re: Termination of Joint Filing and Solicitation Agreement, dated November 27, 2020 Dear Craig: The undersigned constitute all the parties to that certain Joint Filing and Solicitation Agreement, dated November 27, 2020 (the ?A |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15) Enzo Biochem, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294100102 (CUSIP Number) James C. Roumell Asset Management, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 (301) 656-8500 (Name, Address and Telephone Number of Pers |
|
| August 20, 2021 |
ENZ / Enzo Biochem, Inc. / Wolf James G. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT §240.13d-2 (Amendment No. ) ENZO BIOCHEM, INC. (Name of Issuer) Common Stock $.01 Par Value (Title of Class of Securities) 294100102 (CUSIP Number) August 10, 2021 (Date of Eve |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 11-K FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ? ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 1 |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2021 Enzo Biochem, Inc. |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark one ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-09974 ENZO BIOCHEM |
|
| June 11, 2021 |
Conference call and live webcast scheduled for today, Wednesday, June 9, 2021 at 4:30 PM (ET). Exhibit 99.1 Enzo Biochem Reports Third Quarter Fiscal 2021 Results ? Total third quarter revenue of $32.8 million, a record quarterly high, increased 94% year-over-year ? Consolidated quarterly gross margin was 49% versus 26% in the previous year period, confirming Enzo?s vertically integrated approach can continue to drive healthy margins in a post pandemic environment ? Third consecutive quarte |
|
| June 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 9, 2021 Enzo Biochem, Inc. |
|
| May 5, 2021 |
Exhibit 99.1 ROUMELL ASSET MANAGEMENT, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 May 5, 2021 BY OVERNIGHT DELIVERY AND E-MAIL Enzo Biochem, Inc. 527 Madison Avenue New York, New York 10022 Attn: Ian B. Walters, M.D., member of the Board of Directors Mary Tagliaferri, M.D., member of the Board of Directors Rebecca J. Fischer, member of the Board of Directors Dov Perlysky, member of th |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14) Enzo Biochem, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 294100102 (CUSIP Number) James C. Roumell Roumell Asset Management, LLC 2 Wisconsin Circle, Suite 700 Chevy Chase, MD 20815 (301) 656-8500 (Name, Address and Telephone Number |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 19, 2021 Enzo Biochem, Inc. |
